Replies to post #423659 on Amarin Corp Plc (AMRN)

[exwannabe]

1) to what molecule was he referring?

Sounded like he said "... point of departure in that we have semaglutide". That is Wegovi.

2) Could Novo Nordisk’s goal to establish a presence in the cardiovascular space in 2025, and Amarin’s BOD objective to “accelerate operational momentum”, that is execution in the short-term, converge?

Would be nice, but for now we need for AMRN to keep on plugging away and do what is in their control.